KZR vs. ACRV, ACRS, AMRN, IPHA, FULC, OCGN, CYBN, IKT, TLSA, and LRMR
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), Amarin (AMRN), Innate Pharma (IPHA), Fulcrum Therapeutics (FULC), Ocugen (OCGN), Cybin (CYBN), Inhibikase Therapeutics (IKT), Tiziana Life Sciences (TLSA), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.
Kezar Life Sciences vs.
Acrivon Therapeutics (NASDAQ:ACRV) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
Acrivon Therapeutics has higher earnings, but lower revenue than Kezar Life Sciences. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Kezar Life Sciences received 102 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.22% of users gave Acrivon Therapeutics an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote.
Acrivon Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Kezar Life Sciences had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 6 mentions for Kezar Life Sciences and 5 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.22 beat Kezar Life Sciences' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media.
Acrivon Therapeutics presently has a consensus target price of $23.67, suggesting a potential upside of 339.08%. Kezar Life Sciences has a consensus target price of $39.50, suggesting a potential upside of 600.35%. Given Kezar Life Sciences' higher possible upside, analysts plainly believe Kezar Life Sciences is more favorable than Acrivon Therapeutics.
Acrivon Therapeutics' return on equity of -47.95% beat Kezar Life Sciences' return on equity.
Summary
Acrivon Therapeutics beats Kezar Life Sciences on 10 of the 16 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KZR) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy KZR Stock Free KZR Stock Alerts